Skip to main content
. Author manuscript; available in PMC: 2015 Jun 10.
Published in final edited form as: Clin Chim Acta. 2014 Mar 22;433:157–168. doi: 10.1016/j.cca.2014.03.016

Table 3.

Concordance of results obtained using the Exactive-MS method and LC-MS/MS methods for analysis of plasma samples from a clinical trial.

Analyte LOI by LC-MS/MS (ng/ml) LOI by Exactive-MS (ng/ml) Positive by LC-MS/MS Only (n) Positive by Exactive-MS Only (n) Positive by Exactive-MS and LC-MS/MS (n) Negative by Exactive-MS and LC-MS/MS (n) Concordance (Percent Agreement, %)
Protease Inhibitors (PIs)
Ataznavir 100 5 0 0 5 59 100
Ritonavir 100 5 0 1 2 61 98.4
Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Emtricitabine 5 10 0 0 11 53 100
Lamivudine 20 5 2 0 26 36 96.8
Tenofovir 5 10 0 1 9 54 98.4
Zidovudine 5 10b 6 1 8 49 89.1
Non-Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Efavirenz 100 150 0 0 13 51 100
Nevirapine 20 5 2 1 15 46 95.3
Analyte LOI by LC-MS/MS (ng/ml) LOI by Exactive-MS (ng/ml) Positive by LC-MS/MS Only (n) Positive by Exactive-MS Only (n) Positive by Exactive-MS and LC-MS/MS (n) Negative by Exactive-MS and LC-MS/MS (n) Concordance (Percent Agreement, %)
Protease Inhibitors (PIs)
Ataznavir 100 5 0 0 5 59 100
Ritonavir 100 5 0 1 2 61 98.4
Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Emtricitabine 5 10 0 0 11 53 100
Lamivudine 20 5 2 0 26 36 96.8
Tenofovir 5 10 0 1 9 54 98.4
Zidovudine 5 10b 6 1 8 49 89.1
Non-Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Efavirenz 100 150 0 0 13 51 100
Nevirapine 20 5 2 1 15 46 95.3
Analyte LOI by LC-MS/MS (ng/ml) LOI by Exactive-MS (ng/ml) Positive by LC-MS/MS Only (n) Positive by Exactive-MS Only (n) Positive by Exactive-MS and LC-MS/MS (n) Negative by Exactive-MS and LC-MS/MS (n) Concordance (Percent Agreement, %)
Protease Inhibitors (PIs)
Ataznavir 100 5 0 0 5 59 100
Ritonavir 100 5 0 1 2 61 98.4
Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Emtricitabine 5 10 0 0 11 53 100
Lamivudine 20 5 2 0 26 36 96.8
Tenofovir 5 10 0 1 9 54 98.4
Zidovudine 5 10b 6 1 8 49 89.1
Non-Nucleotide/Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
Efavirenz 100 150 0 0 13 51 100
Nevirapine 20 5 2 1 15 46 95.3

a. The LC-MS/MS method included an isotopically-labeled internal standard for zidovudine and monitors fragments at a limit of identification of 5 ng/ml. The full scan-HRMS does not monitor fragments < 50 ng/ml.

b

The LC-MS/MS method included an isotopically-labeled internal standard for zidovudine and monitors fragments at a limit of identification of 5 ng/ml. The full scan-HRMS does not monitor fragments < 50 ng/ml.

a. The LC-MS/MS method included an isotopically-labeled internal standard for zidovudine and monitors fragments at a limit of identification of 5 ng/ml. The full scan-HRMS does not monitor fragments <50 ng/ml.